| 000 | 01917 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516112714.0 | ||
| 264 | 0 | _c20131217 | |
| 008 | 201312s 0 0 eng d | ||
| 022 | _a1540-8183 | ||
| 024 | 7 |
_a10.1111/j.1540-8183.2012.00766.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHermiller, James B | |
| 245 | 0 | 0 |
_aSustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study. _h[electronic resource] |
| 260 |
_bJournal of interventional cardiology _cDec 2012 |
||
| 300 |
_a565-75 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
| 650 | 0 | 4 |
_aCardiovascular Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCoronary Artery Disease _xtherapy |
| 650 | 0 | 4 | _aDrug-Eluting Stents |
| 650 | 0 | 4 | _aEverolimus |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMyocardial Infarction _xepidemiology |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aSirolimus _xadministration & dosage |
| 650 | 0 | 4 |
_aThrombosis _xepidemiology |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 700 | 1 | _aRutledge, David R | |
| 700 | 1 | _aGruberg, Luis | |
| 700 | 1 | _aKatopodis, John N | |
| 700 | 1 | _aLombardi, William | |
| 700 | 1 | _aMao, Vivian W | |
| 700 | 1 | _aZhao, Weiying | |
| 700 | 1 | _aSharma, Samin K | |
| 700 | 1 | _aTamboli, Hoshedar P | |
| 700 | 1 | _aWang, Jin | |
| 700 | 1 | _aJonnavithula, Lalitha | |
| 700 | 1 | _aSudhir, Krishnankutty | |
| 700 | 1 | _aKrucoff, Mitchell W | |
| 773 | 0 |
_tJournal of interventional cardiology _gvol. 25 _gno. 6 _gp. 565-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1540-8183.2012.00766.x _zAvailable from publisher's website |
| 999 |
_c22123435 _d22123435 |
||